MARIPOSA 2 Flashcards
1
Q
what is the Title of MARIPOSA 2
A
Amivantamab plus chemotherapy with and without Lazertinib in EGFR-mutant advanced NSCLC after disease progresion on Osimertinib
2
Q
what is the Design of M2
A
global, randomized, phase 3 trial assessing the efficacy and safety of Ami + chemo & Ami + chemo + Lazertinib vs chemo in patients with EGFR-mutated advanced NSCLC who have progressed on or after Osi monotherapy
3
Q
how many total patients were in M2
A
657
4
Q
what were the Dual Primary Endpoints of M2
A
- PFS for Ami + Chemo (6.3 mo.) vs. chemo (4.2 mo.)
- PFS for Ami + Chemo + Lazertinib (8.2 mo.) vs. chemo (4.2 mo.)
5
Q
what were the Dual Secondary Endpoints of M2
A
- ORR for Ami + chemo (64%) vs. chemo (36%)
- ORR for Ami + chemo + Lazertinib (63%) vs. chemo (36%)
6
Q
what was the Intracranial PFS of M2
A
- PFS for Ami + Chemo (12.5 mo.) vs. chemo (8.3 mo.)
- PFS for Ami + Chemo + Lazertinib (12.8 mo.) vs. chemo (8.3 mo.)
7
Q
A
